schizophrenia

Displaying 1 - 6 of 6

Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark.  

Related Categories: 
Aaron Bender Allison Gregro Basic Sciences biomedical research Carrie Jones clinical trial Colleen Niswender Craig Lindsley Darren Engers Discovery Vanderbilt Research Press release Food and Drug Administration Jeffrey Conn Jerri Rook Julie Engers Kayla Temple neuroscience Olivier Boutaud Pharmacology schizophrenia School of Medicine Basic Sciences Thomas Bridges Warren Center for Neuroscience Drug Discovery

Vanderbilt inks collaboration with Neumora Therapeutics, Inc to continue development of investigational treatment for neuropsychiatric disorders

Vanderbilt inks collaboration with Neumora Therapeutics, Inc to continue development of investigational treatment for neuropsychiatric disorders

Related Categories: 
Neumora Health and Medicine Research Aaron Bender Allison Gregro Basic Sciences Carrie Jones clinical pharmacology Colleen Niswender Craig Lindsley Darren Engers dopamine Jerri Rook Julie Engers Kayla Temple neuropsychiatric disorders Olivier Boutaud P. Jeffrey Conn precision medicine schizophrenia Tom Bridges WCNDD Warren Center for Neuroscience Drug Discovery

A potential new approach for the treatment of schizophrenia

A potential new approach for the treatment of schizophrenia

Related Categories: 
Health and Medicine Research Basic Sciences Canadian Institutes for Health Research Doctoral Foreign Study Award cell reports Colleen Niswender Craig Lindsley James Maksymetz Jeff Conn National Institutes of Health Pharmacology schizophrenia the Vanderbilt Murine Neurobehavior Core Vanderbilt Cell Imaging Shared Resource Vanderbilt International Scholars Program Vanderbilt University Institute of Imaging Science WCNDD

Researchers find high-risk genes for schizophrenia

Using a unique computational framework they developed, a team of scientist cyber-sleuths in the Vanderbilt University Department of Molecular Physiology and Biophysics and the Vanderbilt Genetics Institute (VGI) has identified 104 high-risk genes for schizophrenia.

Related Categories: 
Bingshan Li James Sutcliffe molecular physiology and biophysics Nancy Cox Nature Neuroscience Qiang Wei Quan Wang Rui Chen schizophrenia Xue Zhong

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Related Categories: 
schizophrenia Boehringer Ingelheim Vanderbilt Center for Neuroscience Drug Discovery VCNDD

Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Vanderbilt University has signed separate licensing and research collaboration agreements with Lundbeck, a global pharmaceutical company based in Denmark, to develop a novel approach for treating schizophrenia.

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed by the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) that act on a receptor in the brain that has been implicated in schizophrenia.

Related Categories: 
Lundbeck Vanderbilt University schizophrenia Vanderbilt Center for Neuroscience Drug Discovery VCNDD